KalVista Pharmaceuticals Presents New Data Showing Effectiveness Of Sebetralstat In Reducing Anxiety During Attacks; Supports Need For Oral On-Demand Option To Treat Attacks Earlier And More Often At The 2024 HAEi Global Angioedema Forum
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharmaceuticals presented data at the 2024 HAEi Global Angioedema Forum showing that their investigational drug, sebetralstat, effectively reduces anxiety during hereditary angioedema attacks. The KONFIDENT phase 3 trial demonstrated significant anxiety reduction with sebetralstat compared to placebo, supporting the need for an oral on-demand treatment option.
October 04, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KalVista Pharmaceuticals' sebetralstat has shown effectiveness in reducing anxiety during HAE attacks, as presented at the 2024 HAEi Global Angioedema Forum. This supports the need for an oral on-demand treatment, potentially increasing the drug's market appeal.
The presentation of positive phase 3 trial data for sebetralstat at a major forum highlights its potential as an effective treatment for HAE, particularly in reducing anxiety. This could enhance its marketability and adoption, positively impacting KalVista's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100